Finding Gold In An Unfavored Space: Servier And MicroRNA Start Up Miragen In CV Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Starting with a $45 million upfront, the potential value of this deal, which centers on three pre-clinical cardiovascular targets, could reach up to $1 billion, if the companies meet regulatory and commercial milestones.